The University of Oxford and SomaLogic Announce wide-ranging agreement to use SOMAscan in translational research
The University of Oxford and SomaLogic announced today that they have agreed to undertake a number of collaborative projects that will employ SomaLogic’s proprietary SOMAmer reagents and SOMAscan assay technologies to discover and characterize protein biomarkers for a range of clinical diseases and conditions. In order to maximize the collaborative nature of these projects and accelerate the translation of discoveries into clinical testing, the agreement also includes the build-out of a SOMAscan assay service laboratory at Oxford under the direction of SomaLogic personnel.
“We welcome SomaLogic to Oxford, one of Europe’s largest centers for biotechnology research,” said Simon Lovestone, Professor of Translational Neuroscience. “This agreement is a model for how we can bring together the best of industry, academia and the National Health Service to improve healthcare outcomes for patients in the UK and beyond. SomaLogic will benefit from access to Oxford’s world-leading research to develop and refine its products, while we will benefit from access to technology that can enhance what we do.”
“We are excited to closely join our proteomics technologies and knowledge with the biomedical expertise of Oxford’s world-class researchers,” said Byron Hewett, CEO of SomaLogic. “The massive data that will be generated from this agreement should rapidly lead to new applications of our technologies to the clinical diagnosis and management for many diseases and conditions.”
Compared to other current proteomic technologies, SomaLogic’s platform gives researchers unprecedented power for protein biomarker discovery, diagnostics development, and pharmaceutical innovation. SOMAmer reagents, which are at the center of SomaLogic’s proteomics platform, are a new class of superior protein-binding reagents that combine the best properties of both monoclonal antibodies and traditional aptamers. The SOMAscan assay, which incorporates 1,310 different SOMAmer reagents, efficiently, accurately and rapidly measures proteins across a wide range of concentrations in small volumes of multiple biological sample types, accelerating the discovery of biomarkers across a wide range of diseases and conditions.
Oxford is well placed to exploit the wealth of information generated by the SOMAscan technology. The agreement comes as Oxford completes work on its Big Data Institute, which will focus on the analysis of large data sets in an effort to improve detection, treatment and prevention of a range of conditions, adding to work in the existing Target Discovery Institute, which looks for potential new targets for treatments. Overall, the university’s medical research ranges from initial lab work to clinical application in hospitals and health centers, with centers of excellence investigating a range of conditions from cancer and Alzheimer’s to rare tropical diseases. Much of that research can benefit from further proteomics support.
About Medical Sciences at Oxford University
Oxford University’s Medical Sciences Division is one of the largest biomedical research centers in Europe, with over 2,500 people involved in research and more than 2,800 students. From the genetic and molecular basis of disease to the latest advances in neuroscience, Oxford is at the forefront of medical research. The university is rated the best in the world for medicine and life sciences, and it is home to the UK’s top-ranked medical school. It has one of the largest clinical trial portfolios in the UK and great expertise in taking discoveries from the lab into the clinic. Partnerships with the local NHS Trusts enable patients to benefit from close links between medical research and healthcare delivery. More information at www.ox.ac.uk/research
SomaLogic, Inc., is a privately held biomarker discovery and clinical diagnostics company based in Boulder, Colo. The company’s mission is to use its proprietary modified aptamer-based proteomic technologies to develop a wide range of enhanced protein-analysis tools and reagents for the life sciences community; to facilitate biomarker discovery and validation for diagnostic and therapeutic applications; and to develop and commercialize clinical diagnostic products that will improve the delivery of health care by offering timely and accurate diagnostic information to physicians and their patients. Further information about SomaLogic can be found at www.somalogic.com